Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOHARM-MTD: Hydroxyurea Dosing in Sickle Cell Anemia
NCT03128515Phase 3Completed
- Sponsor
- Indiana University
- Start
- Jul 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Indiana University. Primary endpoint: Proportion of children with average hemoglobin ≥9.0 g/dL or average HbF ≥20% at 24 months. Started Jul 2017; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT03128515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128515.